biostudies-literaturede Vette SPMNIDCR NIH HHSNCI NIH HHSZonMw107224https://www.ebi.ac.uk/biostudies/studies/S-EPMC11950982biostudies-literatureUnknown163<h4>Background/purpose</h4>Normal tissue complication probability (NTCP) models can be used to guide radiation therapy (RT) decisions by estimating side-effect risks pretreatment to minimize (late) side-effects. Recently, a comprehensive individual toxicity risk (CITOR) profile of NTCP models addressing common side-effects in head and neck cancer (HNC) patients was developed. This study investigates the generalizability of these models in an international setting, with different treatment approaches and side-effect assessments, promoting their integration into more widespread clinical practice.<h4>Materials/methods</h4>From a prospective registry study, 407 HNC patients were included who were treated with definitive RT with or without systemic therapy between 2015 and 2022. NTCP models preOral oncologyEvaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.PMC11950982P01 CA285249P30 CA016672R01 CA258827R21 CA273984R01 DE028290K01 DE03052409150162010173R01 CA257814Steenbakkers RJHMvan Dijk LVde Vette SPMVan den Bosch LNeh HFrederiks MLHeukelom Jvan Rijn-Dekker MIFuller CDHutcheson KAKeijzer Kvan der Schaaf ASijtsema NMLangendijk JAvan Luijk PLi YMoreno ACChu Hvan der Laan HPfalseEvaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.<h4>Background/purpose</h4>Normal tissue complication probability (NTCP) models can be used to guide radiation therapy (RT) decisions by estimating side-effect risks pretreatment to minimize (late) side-effects. Recently, a comprehensive individual toxicity risk (CITOR) profile of NTCP models addressing common side-effects in head and neck cancer (HNC) patients was developed. This study investigates the generalizability of these models in an international setting, with different treatment approaches and side-effect assessments, promoting their integration into more widespread clinical practice.<h4>Materials/methods</h4>From a prospective registry study, 407 HNC patients were included who were treated with definitive RT with or without systemic therapy between 2015 and 2022. NTCP models pre2025-01-01T00:00:00Z2025 Apr2026-06-01T14:42:59.666Z2026-04-08T13:24:15.444ZS-EPMC119509824002398410.1016/j.oraloncology.2025.107224